Akèy › Kansè Metastatik › Arizona › Tucson
Etid klinik pou Kansè Metastatik nan Tucson, AZ
14 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Tucson (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Ap rekriteFaz 1
- University of Arizona Cancer Center, Tucson
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- The University of Arizona Cancer Center, Tucson
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- University of Arizona-Cancer Center, Tucson
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of Arizona - Cancer Center, Tucson
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Arizona Cancer Center at University of Arizona, Tucson
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Tucson
Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers
Ap rekrite
- University of Arizona Cancer Center, Tucson
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- The University of Arizona Cancer Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Arizona Cancer Center, Tucson
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Arizona, Tucson
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Tucson
- Kansè nan tete20 etid
- Obèsite18 etid
- Kansè Poumon ki pa ti selil17 etid
- Sipwa15 etid
- Kansè (tout kalite)12 etid
- Maladi kadyovaskilè12 etid
- Kansè kolorektal11 etid
- Kansè pwostat11 etid
- Dyabèt Tip 211 etid
- Maladi fwa steatotik10 etid
- Ensifizyans kadyak10 etid
- Hypertension artérielle10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.